Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Robotic surgery specialist Intuitive Surgical missed profit expectations when it reported first-quarter results late last week as customers shifted from purchasing robots to leasing them, and shares fell 7%.

Intuitive Surgical misses on profit

There's a lot to like about the company behind the groundbreaking daVinci robotic surgical system -- but there are important caveats to consider, too.

Is Intuitive Surgical (ISRG) a Buy?

Shares of robotic surgical systems maker Intuitive Surgical, Inc. were tumbling below the $500 handle Monday for the first time since late January following the release of its quarterly results after the close Thursday.

Raymond James Stays Bullish As Intuitive Surgical Falls On Quarterly Results: 'We Would Buy On Any Weakness'

Intuitive Surgical Deals With Profit Pressure

Could this be a fully subscription business in a decade?

Part of Intuitive Surgical's Business Model Is Evolving

Intuitive Surgical's (ISRG) Q1 results outside the United States impress.

Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates

An earnings miss for the robotic surgical systems pioneer isn't a big deal at all.

5 Reasons You Don't Need to Worry About Intuitive Surgical's Q1 Earnings Miss

Celgene

Illumina

Teladoc

Vertex Pharmaceuticals

Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.

5 Top Healthcare Stocks to Buy in 2019

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q1 2019 Results - Earnings Call Transcript

Intuitive Surgical Inc.  shares dropped in the extended session Thursday after the surgical robot maker's quarterly results fell short of Wall Street estimates.

Intuitive Surgical stock falls after earnings miss

Intuitive Surgical stock crashed late Thursday after the surgical robotics firm's quarterly sales missed estimates. Intuitive Surgical earnings also lagged.

Robotic Surgery Giant Intuitive Surgical Crashes On First-Quarter Miss

Intuitive Surgical, Inc. (NASDAQ: ISRG) shares are down after reporting a first-quarter earnings miss.

Intuitive Surgical Shares Fall After Q1 Earnings Miss

Alnylam Pharmaceuticals

Arena Pharmaceuticals

Medical stocks continued a two-day plunge Thursday on worries over a Bernie Sanders proposal for a single-payer health care system called "Medicare for All."

Medical Stocks Blistered On Sanders Proposal — Is This A Correction?

DexCom

Ionis Pharma

Masimo

Madrigal Pharmaceuticals

Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.

Medical Stocks Charred As They 'Feel The Bern' Of Single-Payer Proposal

A lot will change over the next 10 years. Those changes should be good for Intuitive Surgical overall.

Where Will Intuitive Surgical (ISRG) Be in 10 Years?

Intuitive Surgical's Systems and Services revenues are likely to boost Q1 results.

Will Instruments Drive Intuitive Surgical Q1 Earnings?

ABIOMED

Align Technology

Tandem Diabetes Care

Medical device stocks were hot in 2018. Here's which ones could sizzle in 2019.

5 Top Medical Device Stocks for 2019

Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical (ISRG) Reports Next Week: Wall Street Expects Earnings Growth

A couple of notable developments since the last earnings report should be of interest to investors.

What's on Tap When Intuitive Surgical Reports Earnings Next Week?

Accuray

Which medical-device titan is more worthy of your investment dollars today?

Better Buy: Intuitive Surgical (ISRG) vs. Accuray (ARAY)

Intuitive Surgical has shown strong growth over the years with more growth expected in the future.

Intuitive Surgical: A Company Of The Future, But Its Stock Is Expensive

Intuitive Surgical could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market.

Intuitive Surgical Upside If da Vinci Systems Reaches 25% Share In Global Surgical Robots Market?

Biogen

CVS Health

What do a beaten-down biotech, a giant pharmacy chain, and a robotic surgical systems maker have in common? They could all be great stocks to buy.

Healthcare Stocks to Buy Right Now

These two companies have been super-successful in their niche markets. But which is the better pick for long-term investors?

News for Intuitive Surgical Stock (ISRG)